Skip to main
PEPG

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PepGen is a promising biotechnology company with a unique platform for delivering oligonucleotide therapeutics to a wide range of target tissues, including the central nervous system. While the recent clinical data from their PGN-EDODM1 drug is still early and somewhat complicated to interpret, their ability to improve tissue concentrations and show improvements in clinical function is encouraging. There may be some concerns about the safety profile, but overall, PepGen is well-positioned to advance in the biotech market and has the potential for significant growth as they continue to pursue their pipeline of drugs for severe neuromuscular diseases.

Bears say

PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform for improving the uptake and activity of conjugated oligonucleotide therapeutics. However, the company's recent FREEDOM-2 study results for its lead product PGN-EDODM1 are difficult to interpret and reflect early-stage data. With the upcoming 10mg/kg data from FREEDOM-2 expected to establish a "go/no-go" decision for the program and the company's shares trading below their target, a negative outlook is warranted until further clarity is provided.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Strong Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.